Fast, ready-to-use migraine pain relief1-3
Tosymra delivers migraine pain relief in as little as 10 minutes with just one spray for some patients (13% vs. 5% for placebo).*1-3
Efficacy of Tosymra is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.1
*Time to onset and degree of pain relief varies by patient.
Tosymra uses the science of Intravail®
Tosymra is the first and only triptan nasal spray to use the novel ingredient Intravail® to enhance drug absorption across the nasal mucosa.4
Tosymra for free†
The Access Pathways® Program is a best-in-class savings and support program. Access Pathways®, in partnership with Blink Pharmacy Plus, offers:
Eligible patients pay $0† per prescription, only available through Blink Pharmacy Plus
Dedicated customer support to guide you and your patients through the process
†Restrictions and quantity limits apply. Click to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.
Want more information?
Sign up today to learn more about Tosymra.
- Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
- Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
- Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.
- Maggio ET. Intravail®: highly effective intranasal delivery of peptide and protein drugs. Expert Opinion Drug Delivery. 2006;3(4):529-539.